Niagen Bioscience Inc
NAGE6.510USD
-0.200-2.98%
Close 12/23, 16:00（ET）Quotes delayed by 15 min
518.45MMarket Cap
24.82P/E TTM
More Details of Niagen Bioscience Inc Company
Niagen Bioscience, Inc., formerly Chromadex Corp., is a global bioscience company. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. The Company’s Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients directly to consumers and distributors and offers NAD+ test kits exclusively to healthcare practitioners. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and United States FDA-registered 503B outsourcing facilities, respectively. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
Niagen Bioscience Inc Info
Ticker SymbolNAGE
Company nameNiagen Bioscience Inc
IPO dateJun 25, 2007
CEOFried (Robert N)
Number of employees104
Security typeOrdinary Share
Fiscal year-endJun 25
Address10900 Wilshire Blvd Suite 600
CityLOS ANGELES
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code90024
Phone13103886706
Websitehttps://www.niagenbioscience.com/
Ticker SymbolNAGE
IPO dateJun 25, 2007
CEOFried (Robert N)
Company Executives of Niagen Bioscience Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Robert N. (Rob) Fried
Mr. Robert N. (Rob) Fried
Chief Executive Officer, Director
Chief Executive Officer, Director
1.65M
+4.22%
Mr. Ozan Pamir
Mr. Ozan Pamir
Chief Financial Officer
Chief Financial Officer
7.37K
+153.59%
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Lead Independent Director
Lead Independent Director
7.00K
--
Mr. Carlos Luis Lopez
Mr. Carlos Luis Lopez
Senior Vice President, General Counsel
Senior Vice President, General Counsel
2.25K
--
Mr. Ben Shamsian
Mr. Ben Shamsian
Investor Relations
Investor Relations
--
--
Ms. Ann Cohen
Ms. Ann Cohen
Independent Director
Independent Director
--
--
Mr. Gary Ng
Mr. Gary Ng
Independent Director
Independent Director
--
--
Ms. Wendy Yu
Ms. Wendy Yu
Independent Director
Independent Director
--
--
Ms. Kristin Patrick
Ms. Kristin Patrick
Independent Director
Independent Director
--
--
Mr. Hamed Shahbazi
Mr. Hamed Shahbazi
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Robert N. (Rob) Fried
Mr. Robert N. (Rob) Fried
Chief Executive Officer, Director
Chief Executive Officer, Director
1.65M
+4.22%
Mr. Ozan Pamir
Mr. Ozan Pamir
Chief Financial Officer
Chief Financial Officer
7.37K
+153.59%
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Lead Independent Director
Lead Independent Director
7.00K
--
Mr. Carlos Luis Lopez
Mr. Carlos Luis Lopez
Senior Vice President, General Counsel
Senior Vice President, General Counsel
2.25K
--
Mr. Ben Shamsian
Mr. Ben Shamsian
Investor Relations
Investor Relations
--
--
Ms. Ann Cohen
Ms. Ann Cohen
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Brilliant Dynasty Ltd
14.30%
Pioneer Step Holdings, Ltd.
8.67%
The Vanguard Group, Inc.
5.02%
Nestle Health Science US Holdings, Inc.
4.78%
BlackRock Institutional Trust Company, N.A.
4.37%
Other
62.86%
Shareholders
Shareholders
Proportion
Brilliant Dynasty Ltd
14.30%
Pioneer Step Holdings, Ltd.
8.67%
The Vanguard Group, Inc.
5.02%
Nestle Health Science US Holdings, Inc.
4.78%
BlackRock Institutional Trust Company, N.A.
4.37%
Other
62.86%
Shareholder Types
Shareholders
Proportion
Corporation
31.56%
Investment Advisor
19.17%
Investment Advisor/Hedge Fund
13.94%
Hedge Fund
5.70%
Individual Investor
2.44%
Research Firm
1.42%
Pension Fund
0.68%
Bank and Trust
0.23%
Venture Capital
0.07%
Other
24.79%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
277
29.97M
37.55%
+806.79K
2025Q2
256
54.09M
67.83%
+1.52M
2025Q1
248
52.79M
67.45%
+991.43K
2024Q4
227
50.32M
64.79%
+3.69M
2024Q3
187
45.29M
58.88%
-2.22M
2024Q2
176
44.12M
58.29%
+362.19K
2024Q1
173
40.79M
55.40%
+2.41M
2023Q4
177
39.03M
53.11%
+1.29M
2023Q3
191
38.74M
52.74%
+56.61K
2023Q2
203
38.69M
53.76%
+732.31K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Brilliant Dynasty Ltd
11.41M
14.31%
+11.41M
--
Aug 20, 2024
Pioneer Step Holdings, Ltd.
6.92M
8.67%
--
--
Aug 20, 2024
The Vanguard Group, Inc.
3.92M
4.92%
+383.90K
+10.84%
Jun 30, 2025
Nestle Health Science US Holdings, Inc.
3.82M
4.79%
--
--
Apr 25, 2025
BlackRock Institutional Trust Company, N.A.
3.44M
4.31%
+105.31K
+3.16%
Jun 30, 2025
Black Sheep, FLP
2.08M
2.6%
--
--
Apr 25, 2025
Tieton Capital Management, LLC
1.58M
1.98%
-404.73K
-20.38%
Jun 30, 2025
Fried (Robert N)
1.65M
2.06%
+66.67K
+4.22%
Apr 25, 2025
Arrowstreet Capital, Limited Partnership
1.12M
1.4%
+129.51K
+13.08%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.30M
1.62%
+116.27K
+9.86%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Insider Advantage ETF
0.98%
Gabelli Love Our Planet & People ETF
0.27%
ALPS Barron's 400 ETF
0.2%
Even Herd Long Short ETF
0.11%
Principal U.S. Small-Cap ETF
0.08%
iShares Micro-Cap ETF
0.08%
Vanguard US Quality Factor ETF
0.07%
Vanguard US Momentum Factor ETF
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
WisdomTree US SmallCap Quality Growth Fund
0.06%
View more
AdvisorShares Insider Advantage ETF
Proportion0.98%
Gabelli Love Our Planet & People ETF
Proportion0.27%
ALPS Barron's 400 ETF
Proportion0.2%
Even Herd Long Short ETF
Proportion0.11%
Principal U.S. Small-Cap ETF
Proportion0.08%
iShares Micro-Cap ETF
Proportion0.08%
Vanguard US Quality Factor ETF
Proportion0.07%
Vanguard US Momentum Factor ETF
Proportion0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.06%
WisdomTree US SmallCap Quality Growth Fund
Proportion0.06%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Niagen Bioscience Inc?
The top five shareholders of Niagen Bioscience Inc are:
Brilliant Dynasty Ltd holds 11.41M shares, accounting for 14.31% of the total shares.
Pioneer Step Holdings, Ltd. holds 6.92M shares, accounting for 8.67% of the total shares.
The Vanguard Group, Inc. holds 3.92M shares, accounting for 4.92% of the total shares.
Nestle Health Science US Holdings, Inc. holds 3.82M shares, accounting for 4.79% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.44M shares, accounting for 4.31% of the total shares.
Brilliant Dynasty Ltd holds 11.41M shares, accounting for 14.31% of the total shares.
Pioneer Step Holdings, Ltd. holds 6.92M shares, accounting for 8.67% of the total shares.
The Vanguard Group, Inc. holds 3.92M shares, accounting for 4.92% of the total shares.
Nestle Health Science US Holdings, Inc. holds 3.82M shares, accounting for 4.79% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.44M shares, accounting for 4.31% of the total shares.
What are the top three shareholder types of Niagen Bioscience Inc?
The top three shareholder types of Niagen Bioscience Inc are:
Brilliant Dynasty Ltd
Pioneer Step Holdings, Ltd.
The Vanguard Group, Inc.
Brilliant Dynasty Ltd
Pioneer Step Holdings, Ltd.
The Vanguard Group, Inc.
How many institutions hold shares of Niagen Bioscience Inc (NAGE)?
As of 2025Q3, 277 institutions hold shares of Niagen Bioscience Inc, with a combined market value of approximately 29.97M, accounting for 37.55% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -30.28%.
What is the biggest source of revenue for Niagen Bioscience Inc?
In --, the -- business generated the highest revenue for Niagen Bioscience Inc, amounting to -- and accounting for --% of total revenue.
